Tirzepatide is generally not recommended during active Crohn's flares because the medication slows stomach emptying and may worsen cramping or diarrhea
Possible risks if self-used incorrectly include mineral imbalance (copperzinc), skin irritation or hypersensitivity, and incorrect dosing with injectables
Novo Nordisk A/S: Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss [Press release]
It also notes that people taking certain diabetes or thyroid medications should confirm safety with a provider first
Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript
